Beating COVID-19 With The Pacer BioThreat Strategy ETF (Podcast)
Rushed to market just 6 months into the COVID-19 pandemic, the Pacer BioThreat Strategy ETF (VIRS) takes a unique approach to picking potential pandemic winners.The LifeSci BioThreat Strategy Index underlying VIRS selects holdings based on seven different criteria - everything from potential vaccine makers to companies powering the transition to a work-from-home economy.Pacer ETFs President Sean O’Hara joins the podcast to explain why his firm's newest fund is designed to protect investor portfolios from pandemics, both present and future.
Seekingalpha · 59m ago
Abbott (ABT) Stock Moves -1.98%: What You Should Know
Abbott (ABT) closed the most recent trading day at $102.73, moving -1.98% from the previous trading session.
Zacks · 14h ago
FOCUS-Positive about flying? Airlines look to COVID tests that give results in minutes
Reuters · 1d ago
Lufthansa plans rapid COVID-19 testing starting October -executive
Deutsche Lufthansa AG plans to start making rapid COVID-19 antigen tests available to passengers in October and is weighing the option of opening test centres at airports in the United States and Canada, a company executive said on Tuesday. While the aviation industry has largely backed the use of Polymerase
Reuters · 1d ago
Siemens Healthineers Expanding The Business, But Self-Help Is Still Needed
Siemens Healthineers' proposed acquisition of Varian still makes sense, even if the market hasn't loved it, and will add a complementary quality growth driver to the business.After several years of underperformance and share loss, the diagnostics business needs a concerted turnaround effort, and the new Atellica platform won't do it all on its own.The imaging business is a top-quality operation, with #1 or nearly-#1 share in most major markets, strong margins, and low-to-mid-single-digit growth potential.Valuation on Siemens Healthineers is okay but not compelling at today's price, but the quality of the imaging business and turnaround potential in diagnostics are worth watching.
Seekingalpha · 1d ago
Stock-market ‘anxiety will only intensify over the next 60-90 days’ warns expert who profited in 1987 and 2008 crises
Contrarian money manager Alan B. Lancz, who is a disciple of famed investor John Templeton, says that stocks aren't likely to see any substantial gains in... · 1d ago
4 Best Diabetes Device Stocks to Focus on Amid Coronavirus Crisis
Here are a few diabetes-centric MedTech stocks that investors can focus on to reap profits amid the pandemic-battered stock market situation.
Zacks · 1d ago
Abbott Tacks On Massive Coronavirus Test Growth — But Is ABT Stock A Buy?
Investor's Business Daily · 2d ago
Abbott Launches Sports Biosensor in Europe, Boosts CGM Wing
Abbott (ABT) makes its first non-exclusive collaboration with Atlanta-based sports technology company, Supersapiens.
Zacks · 2d ago
Abbott Hosts Conference Call for Third-Quarter Earnings
Abbott (NYSE: ABT) will announce its third-quarter 2020 financial results on Wednesday, Oct. 21, 2020, before the market opens.
PR Newswire · 2d ago
Abbott receives CE mark approval for MitraClip G4 to treat mitral regurgitation
Abbott (ABT) -0.8% fourth-generation MitraClip™ Transcatheter Mitral Valve Repair System has received CE marking.MitraClip G4 device already approved in US is now approved for use in Europe and other countries as a non-surgical option for the
Seekingalpha · 2d ago
Abbott MitraClip G4 OK'd in Europe for leak in heart valve
Abbott Laboratories (ABT) has received CE Mark for its fourth-generation MitraClip Transcatheter Mitral Valve Repair System.Known as MitraClip G4, the device is now approved for use in Europe and other countries that
Seekingalpha · 2d ago
Abbott Receives CE Mark For MitraClip Heart Valve Repair Device To Treat Mitral Regurgitation
ABBOTT PARK, Ill., Sept. 21, 2020 /PRNewswire/ --Abbott (NYSE:ABT) today announced it has received CE Mark for its fourth-generation MitraClip™ Transcatheter Mitral Valve Repair System, the leading
Benzinga · 2d ago
Abbott Receives CE Mark for Next-Generation MitraClip™ Heart Valve Repair Device to Treat Mitral Regurgitation
Abbott (NYSE: ABT) today announced it has received CE Mark for its fourth-generation MitraClip™ Transcatheter Mitral Valve Repair System, the leading minimally invasive mitral valve repair device in the world. Known as MitraClip G4, the device is now approved for use in Europe and other countries that
PR Newswire · 2d ago
DexCom: A Superior Business Model But Watch Out For Debt Level
DexCom produces continuous glucose monitoring devices.The stock price has increased steeply in the last one year, but a slight dip recently constitutes an opportunity for investors.The medical devices company has enjoyed double-digit growth and looks likely to continue when considering the business model.It has a high level of product differentiation compared with competitors but debt level is also higher.The stock has the potential to climb much higher.
Seekingalpha · 3d ago
Is Sorrento Stock Really Worth the Speculation?
Until this year, Sorrento Therapetics (NASDAQ:SRNE) was an obscure biotech operator. But this changed with the emergence with the novel coronavirus. Now SRNE stock has become one of the most controversial, and volatile, biotech stocks in the market.Source: Shutterstock From May until early August, Sorrento
InvestorPlace · 5d ago
Cramer Advises Viewers On Peloton, Vale And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said NextEra Energy Inc (NYSE: NEE) is the fastest-growing growth utility. If you want a growth utility that is the one.
Benzinga · 5d ago
20/20 GeneSystems Stock: Leveraging AI for More Accurate Cancer Screening
20/20 GeneSystems is the developer of diagnostic testing tools for cancer and other diseases. Keep in mind that this startup leverages AI (artificial intelligence) for its systems. Oh, and you can also invest in 20/20 GeneSystems stock through an equity crowdfunding campaign on SeedInvest.Source: Shutterstock
InvestorPlace · 6d ago
Cramer's lightning round: Peloton has run up way too far
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed. · 6d ago
Abbott Declares 387th Consecutive Quarterly Dividend
The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 36 cents per share.
PR Newswire · 6d ago
Webull provides a variety of real-time ABT stock news. You can receive the latest news about Abbott through multiple platforms. This information may help you make smarter investment decisions.
About ABT
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.